Issue 1 2023 9 to the spectacular location of the company’s headquarters in the small town of Bozeman, Montana, which boasts Yellowstone National Park right on its doorstep. This is in addition to being in close proximity to world-class ski resorts and blue-ribbon trout streams. After a rewarding day at work, employees can go cycling around town or play in the company’s rec-league soccer team. Now, the team is keenly looking towards the bright future ahead and are excited to share their ambitious vision for 2023! The company will start 2023 strong by releasing the new version of VSClinical supporting TSO-500 for the AMP guidelines. Andreas says, “This required us to improve our ability to process fusions and other structural variants leveraging break-end notations. As a result, we have been working to harmonize our ability to handle all types of structural variants to be processed across the entire VSClinical platform. We are excited to announce that these capabilities will be available for germline interpretations in the first half of this year.“ He goes on to share, “We are also excited about the future of our Golden Helix CancerKB, a premium annotation source that connects biomarkers with clinical outcomes. Golden Helix CancerKB is an important piece of our company’s commitment to providing our customers with the highest value clinical database possible, ensuring that they have all the information they need to make informed decisions about their treatment options. Our software solution enables our customers to create clinical reports leveraging this information very efficiently.” As the NGS market matures, the requirements for scalable deployments is increasing. The team will continue to analyse the entire underlying software stack to meet the changing scalability requirements of their customers. Company: Golden Helix Contact: Delaina Hawkins Email: [email protected] Website: www.goldenhelix.com
RkJQdWJsaXNoZXIy MTQxNTg3MQ==